Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22334298 | 0.92 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL24383274 | 0.92 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL24130193 | 0.87 | LMNA (0.30) | ALDH1A1LMNASLC15A2 | |
| SCHEMBL25495878 | 0.86 | STING1 (0.31) | — | |
| SCHEMBL17446627 | 0.86 | CYP1A2 (0.42) | ALDH1A1LMNA | |
| SCHEMBL16214319 | 0.81 | ALDH1A1 (0.43) | ALDH1A1PAOXLMNASLC15A2 | |
| SCHEMBL17641641 | 0.79 | KDM4E (0.33) | ALDH1A1LMNA | |
| SCHEMBL984488 | 0.79 | LMNA (0.36) | ALDH1A1LMNA | |
| SCHEMBL437769 | 0.78 | TSHR (0.48) | ALDH1A1LMNA | |
| SCHEMBL9969946 | 0.77 | ALDH1A1 (0.39) | ALDH1A1LMNASLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328310-A1 | SIRNA TARGETING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230279041-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | HONGENE BIOTECH CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-9714421-B2 | Compositions and methods | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170183661-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170159055-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9139456-B2 | Chelating compounds and immobilized tethered chelators | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2015-09-22 | — | — | US | disclosed |
| US-9127276-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150196655-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2015-07-16 | — | — | US | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126720-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20140349952-A1 | MANNOSYLATED COMPOUNDS USEFUL FOR THE PREVENTION AND THE TREATMENT OF INFECTIOUS DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-11-27 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20120061325-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120061325-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | BTD, TTPA, SLC39A7 | ALDH1A1 3904/4885PAOX 1091/4885LMNA 3554/4885 |
| US-20140349952-A1 | MANNOSYLATED COMPOUNDS USEFUL FOR THE PREVENTION AND THE TREATMENT OF INFECTIOUS DISEASES | MANBA, MAN2A1, MAN2B1 | ALDH1A1 2889/4885PAOX 1513/4885LMNA 2051/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | ALDH1A1 1286/4885PAOX 2659/4885LMNA 885/4885 |
| US-20230279041-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | FUT6, CSGALNACT1, GALNT6 | ALDH1A1 1648/4885PAOX 1173/4885LMNA 1037/4885 |
| US-20150196655-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | RNASE1, IGF2BP1, IGF2BP2 | ALDH1A1 2059/4885PAOX 3963/4885LMNA 700/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | ALDH1A1 2955/4885PAOX 3115/4885LMNA 2495/4885 |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | ALDH1A1 3686/4885PAOX 2600/4885LMNA 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.